Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian share markets open firm
Mon, 25 Mar 09:30 am

Barring China (down 0.1%), all major Asian stock markets have opened the day on a firm note with stock markets in Japan (up 1.7%) and South Korea (up 1.4%) leading the gains. The Indian share markets indices have also opened the day on a firm note. Stocks in the oil and gas, realty and power space are leading the gains.

The Sensex today is up by around 137 points (0.7%), while the NSE-Nifty is up by around 45 point (0.8%). Mid and small cap stocks are also trading in the green with the BSE Mid Cap and BSE Small Cap indices up by around 0.9% each. The rupee is trading at Rs 54.35 to the US dollar.

Auto stocks have opened the day on a firm note with Maruti Suzuki, Escorts and Tube Investments leading the gains. As per a leading financial daily, India's leading passenger vehicle maker Maruti Suzuki is now aiming to increase its presence and market share in the fast growing utility vehicle market. Ertiga MPV, its latest offering in the utility vehicle space has become India's largest selling model in the segment. It is also being exported to Indonesia. Maruti is now planning to launch new products and variants in the utility vehicle space. It must be noted that Maruti is a leader in the small car market. It enjoys a hefty 50% market share in the domestic car market. However, competition in the small car segment has been increasing. For instance, companies such as General Motors that have traditionally manufactured big cars have forayed into the hatchback segment.

Indian pharma stocks have opened the day on a firm note with Orchid Chemicals, Fresenius Kabi Oncology and Panacea Biotech leading the gains. As per a leading financial daily, Dr Reddy's Laboratories has received US$ 22.5 m (Rs 1,222.7 m) from Canadian pharmaceutical firm Nordion Inc (formerly known as MDS Inc) as damages from the contract research organization (CRO). Dr Reddy's had filed a suit against the Canadian company in April 2009. It had sought US$ 80 m as damages on account of an alleged breach by the CRO in a laboratory service agreement. It must be noted that the CRO provided lab services related to bio-equivalency studies to support Dr Reddy's regulatory applications for generic drug approvals. The settlement was concluded on March 20, 2013 with the receipt of the settlement funds by Dr Reddy's.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets open firm". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.